Abiopharma

News list

Director ALVAREZ CESAR L 🟢 acquired 94.5K shares (2 derivative) of PRECIGEN, INC. (PGEN) at $3.51 Transaction Date: Mar 10, 2026 | Filing ID: 003682

Full text

News bot March 12, 2026, 8:23 p.m.
🔍 ALVAREZ CESAR L (Director)

Company: PRECIGEN, INC. (PGEN)

Report Date: 2026-03-10
Transaction Summary:
- Total transactions: 3
- Derivative instruments: 2
- Holdings reported: 0
- Total shares acquired: 94,491
Detailed Transactions and Holdings:
- Acquired 17,806 shares of Common Stock at $3.51 per share (Direct)
  Date: 2026-03-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 711,070.00 | transaction_form_type: 4 | Footnotes: F1
- Acquired 35,612 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 35,612.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
- Acquired 41,073 shares of Option to Purchase Common Stock (Right to Buy) at $3.51 per share (Derivative)
  Date: 2026-03-10 | Code: A | Expires: 2036-03-10 | Exercise: 2026-03-10 | equity_swap_involved: 0 | shares_owned_after: 41,073.00 | transaction_form_type: 4
Footnotes:
- F1: The shares were issued to the reporting person in lieu of an annual retainer of $62,500.
- F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.
- F3: The RSUs vest in full on March 10, 2027.